Publications by authors named "Robert Bruette"
Article Synopsis
- The study analyzed treatment patterns and persistence of patients with Crohn's disease (CD) who started biologic therapies over a 3-year period using data from the STATinMED RWD Insights database.
- A total of 2,309 patients were tracked, revealing that Ustekinumab (UST) had the highest persistence rate (61.4%) and Infliximab (IFX) had the highest dose titration rate (76.5%).
- The research highlighted that comorbidities like anemia, anxiety, and depression were prevalent, with notable discontinuation rates for Adalimumab (ADA) at 37.3% compared to other treatments.
Introduction: Patients with brain cancer are at a high risk of developing venous thromboembolism (VTE) and are underrepresented in clinical trials. This study compared the risk of recurrent VTE (rVTE), major bleeding (MB), and clinically relevant non-major bleeding (CRNMB) among VTE cancer patients initiating apixaban, low molecular weight heparin (LMWH), or warfarin stratified by patients with brain vs other cancer types.
Materials And Methods: Active cancer patients initiating apixaban, LMWH, or warfarin within 30 days after VTE diagnosis were identified from 4 US commercial and the Medicare databases.
Background: Patients with venous thromboembolism (VTE) and cancer are at higher risk of recurrent VTE and mortality. Clinical guidelines recommend anticoagulant treatment for these patients. This study assessed trends in outpatient anticoagulant treatment and factors associated with this treatment initiation in outpatient setting among this high-risk patient population.
View Article and Find Full Text PDF